Liang Haihai, Li Xuelian, Wang Lu, Yu Shaonan, Xu Zhidan, Gu Yunyan, Pan Zhenwei, Li Tianyu, Hu Meiyu, Cui Hairong, Liu Xue, Zhang Ying, Xu Chaoqian, Guo Rui, Lu Yanjie, Yang Baofeng, Shan Hongli
Department of Pharmacology (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Harbin, P. R. China.
Cell Physiol Biochem. 2013;32(6):1818-29. doi: 10.1159/000356615. Epub 2013 Dec 16.
BACKGROUND: Arsenic trioxide (As2O3), an ancient drug used in traditional Chinese medicine, has substantial anticancer activities, especially in the treatment of patients suffering from acute promyelocytic leukemia (APL); however the underlying mechanisms are not well understood. METHODS: MTT assay was used to detect the cell viability. Flow Cytometry analysis and caspase-3 activity assay were used to measure apoptosis of APL cells. Caspase-3 and Bax levels were analyzed by western blot and let-7d and miR-766 levels were determined by real-time RT-PCR. RESULTS: As2O3 significantly inhibited cell viability and induced apoptosis in APL cells. Several microRNAs, including let-7d and miR-766, were dysregulated in APL cells treated with As2O3. The expression of caspase-3 and Bax, which are targets of let-7d and miR-766, respectively, were up-regulated in As2O3 treated cells. Transfection of let-7d and miR-766 into NB4 cells decreased the expression of caspase-3 and Bax, respectively. Correspondingly, transfection of these microRNAs increased NB4 cell viability. As2O3 induced degradation of promyelocytic leukemia (PML), and then induced the down-regulation of both let-7d and miR-766 in NB4 cells. CONCLUSIONS: We construct a dysregulated microRNA network involved in As2O3-induced apoptosis in APL. Targeting this network may be a new strategy for the prevention of side effects associated with APL treatment with As2O3.
Cell Physiol Biochem. 2013
Zhonghua Xue Ye Xue Za Zhi. 1997-1
J Natl Cancer Inst. 1998-1-21
Front Pharmacol. 2024-6-4
Front Oncol. 2023-5-2
Invest Ophthalmol Vis Sci. 2020-7-1